Establishment of complement-resistant retroviral vector by homologous restriction factor 20 gene

Gene Therapy

Volumn 5, Issue 2, 1998, Pages 282-285

  Hayashi, S ^a   Emi, N ^a   Okada, H ^b   Nagasaka, T ^a   Yokoyama, I ^a   Takagi, H ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

complement dependent selection; gene therapy; retroviral vector

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; TISSUE PLASMINOGEN ACTIVATOR; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN 3T3; COMPLEMENT SYSTEM; CONTROLLED STUDY; GENETIC TRANSDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0031887692     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300574     Document Type: Article

References (28)

1. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460
2. Anderson WF. Human gene therapy. Science 1992; 256: 808-813.
3. Li X et al. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 1989; 171: 331-341.
4. Yang Z et al. Expression of HLA-DR antigen in human class II mutant B cell lines by double infection with retrovirus vectors. Mot Cell Biol 1987; 7: 3923-3928.
5. Cline MJ et al. Gene transfer in intact animals. Nature 1980; 284: 422-425.
6. Ezzeddine ZD et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
7. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
8. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
9. Takizawa H et al. Species specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur J Immunol 1992; 22: 1943-1946.
10. Lubin DM, Coyne KE. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. J Exp Med 1991; 174: 35-44.
11. Hayashi S et al. Inhibitory effect of double transfection to xeno-endothelial cells using both decay accelerating factor and homologous restriction factor 20 genes on complement-dependent cytolysis. J Surg Res 1996; 61: 165-169.
12. White DJG et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc 1992; 24: 474-476.
13. Okada H et al. 20 kDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun 1989; 162: 1553-1559.
14. Maniatis T, Fritsch FF, Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, 1982, pp 14.5-14.34.
15. Podrazik RM et al. High-level expression of recombinant human tPA in cultured canine endothelial cells under varying conditions of retroviral gene transfer. Ann Surg 1992; 216: 446-453.
16. Atkinson JP, Farries T. Separation of self from non-self in the complement system. Immunol Today 1987; 8: 212-213.
17. Weill BJ et al. The alternative complement pathway in hyperacute rejection. Xeno 1994; 2: 92-94.
18. Kinoshita T et al. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162: 75-92.
19. Seya T et al. Distribution of membrane cofactor protein (MCP) of complement on human peripheral blood cells. Eur J Immunol 1988; 18: 1289-1294.
20. Sakurada C et al. Molecular cloning of the rat complement regulatory protein, 512 antigen. Biochem Biophys Res Commun 1994; 198: 819-826.
21. Rushmere NK et al. Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J 1994; 304: 595-601.
22. Motoyama N et al. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 1992; 22: 2669-2673.
23. Boom BW et al. Decreased expression of decay-accelerating factor on endothelial cells of immune complex-mediated vasculitic skin lesions. J Dermatol Sci 1991; 2: 308-315.
24. Nicholson-Weller A et al. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci USA 1983; 80: 5066-5070.
25. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. New Engl J Med 1986; 314: 329-335.
26. Fodor WL et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153-11157.
27. McCurry KR et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423-427.
28. Harada R et al. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J Immunol 1990; 144: 1823-1828.